<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931682</url>
  </required_header>
  <id_info>
    <org_study_id>LUM-001-C-01</org_study_id>
    <secondary_id>UX068-CL001</secondary_id>
    <nct_id>NCT02931682</nct_id>
  </id_info>
  <brief_title>Observational Study of Males With Creatine Transporter Deficiency</brief_title>
  <acronym>Vigilan</acronym>
  <official_title>Observational Study of Males With Creatine Transporter Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to illustrate the clinical, neuro/electrophysiologic,&#xD;
      biochemical, and developmental status and progression of patients with Creatine Transporter&#xD;
      Deficiency (CTD) and to evaluate the utility of performance-based and other measures in the&#xD;
      CTD population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study designed to determine an appropriate clinical assessment&#xD;
      battery for males with CTD, and to evaluate Magnetic resonance spectroscopy (MRS) along with&#xD;
      other potential biomarkers. It is designed to explore developmental domains of interest and&#xD;
      to examine the feasibility and utility of various neuropsychological assessments to measure&#xD;
      domains of interest, and to identify possible endpoints for interventional studies. Study&#xD;
      will also explore genotype-phenotype correlations.&#xD;
&#xD;
      Clinical adverse events will be monitored throughout the study.&#xD;
&#xD;
      This study was previously posted by Lumos Pharma, which has been transferred to Ultragenyx in&#xD;
      June 2019.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change Over Time Through Month 48 in the Bayley Scales of Infant and Toddler Development, 4th Edition (Bayley-4)</measure>
    <time_frame>Month 48</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Creatine Deficiency, X-linked</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, cerebrospinal fluid, urine and fibroblasts&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community Sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has genomic confirmation of a pathologic mutation in the SLC6A8 gene.&#xD;
&#xD;
          2. Subject is able to complete study-related procedures.&#xD;
&#xD;
          3. Subjects' parents/guardians/caregivers must provide written consent (informed consent)&#xD;
             to study-related procedures, and if appropriate, the subject will provide an assent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has had status epilepticus within 3 months of screening.&#xD;
&#xD;
          2. Subject is unable to comply with the study procedures or with a clinical disease or&#xD;
             laboratory abnormality that in the opinion of the investigator would potentially&#xD;
             increase the risk of participation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ultragenyx Pharmaceutical Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Creatine transporter</keyword>
  <keyword>developmental delay</keyword>
  <keyword>intellectual disability</keyword>
  <keyword>X-linked</keyword>
  <keyword>language</keyword>
  <keyword>seizure</keyword>
  <keyword>observational</keyword>
  <keyword>brain spectroscopy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

